Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 28, 2007

Amsterdam Molecular Therapeutics Obtains License to AMT-020 for Acute Intermittent Porphyria

  • Amsterdam Molecular Therapeutics  (AMT) obtained exclusive, worldwide rights to develop and commercialize AMT-020 as a therapeutic product from UTE CIMA, Proyecto de Biomedicina CIMA, and Digna Biotech (all part of the University of Navarra, Pamplona, Spain). 

    The license allows AMT to initiate the clinical development of AMT-020 to treat acute intermittent porphyria. AMT-020 is an AAV vector gene therapy containing the porphobilinogen deaminase gene, which encodes for the enzyme that is defective in acute intermittent porphyria. This disease is associated with recurrent attacks of abdominal pain, gastrointestinal dysfunction, and neurologic disturbances.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.